Sprycel (dasatinib), a new oral drug for certain forms of leukemia

August 2006

There's lots of excitement about Sprycel (dasatinib), a new oral drug for certain forms of leukemia.

Sprycel is a tyrosine kinase inhibitor...similar to Gleevec, but more potent. It's active against most forms of the kinase enzyme that become resistant to Gleevec.

It'll be used in chronic myeloid leukemia patients...or in those with Philadelphia chromosome-positive leukemia...who are resistant to, or can't take, other treatments.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote